Ruxolitinib, a JAK1/JAK2 inhibitor, has recently been approved for the treatment of steroid-resistant GvHD, but a significant number of patients still suffer from the consequence of GvHD [8]. This evidence concerns the gene JAK2 and graft versus host disease.